Literature DB >> 23530094

Gemtuzumab ozogamicin.

Donna Przepiorka, Albert Deisseroth, Robert Kane, Edvardas Kaminskas, Ann T Farrell, Richard Pazdur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23530094     DOI： 10.1200/JCO.2012.48.1887

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

Review 1.  Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.

Authors:  Sumimasa Nagai; Keiya Ozawa
Journal:  Int J Hematol       Date:  2016-04-15       Impact factor: 2.490

Review 2.  Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.

Authors:  Deepa Jagadeesh; Mitchell R Smith
Journal:  Curr Treat Options Oncol       Date:  2016-10

3.  Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases.

Authors:  Sumimasa Nagai; Keiya Ozawa
Journal:  Invest New Drugs       Date:  2018-02-17       Impact factor: 3.850

4.  Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications.

Authors:  Joseph M Unger; Van T Nghiem; Dawn L Hershman; Riha Vaidya; Michael LeBlanc; Charles D Blanke
Journal:  JAMA Netw Open       Date:  2019-09-04

5.  Unintended Regulatory Caused Early Death-A Difficult Endpoint in Cancer Patient Care and Treatment.

Authors:  Wolfgang E Berdel
Journal:  Cancers (Basel)       Date:  2021-03-22       Impact factor: 6.639

Review 6.  Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.

Authors:  Yurong Lai; Xiaoyan Chu; Li Di; Wei Gao; Yingying Guo; Xingrong Liu; Chuang Lu; Jialin Mao; Hong Shen; Huaping Tang; Cindy Q Xia; Lei Zhang; Xinxin Ding
Journal:  Acta Pharm Sin B       Date:  2022-03-17       Impact factor: 14.903

7.  Comparative untargeted proteomic analysis of ADME proteins and tumor antigens for tumor cell lines.

Authors:  Xiaomei Gu; Qing Xiao; Qian Ruan; Yuezhong Shu; Ashok Dongre; Ramaswamy Iyer; W Griffith Humphreys; Yurong Lai
Journal:  Acta Pharm Sin B       Date:  2017-11-04       Impact factor: 11.413
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.